METHOD FOR THE TREATMENT OF PRIMARY METASTATIC PROSTATE CANCER Russian patent published in 2023 - IPC G01N33/48 A61K31/337 A61K31/192 A61K31/417 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention relates to oncourology and can be used in the treatment of primary metastatic prostate cancer. The method includes performing androgen deprivation therapy alone, in combination with Enzalutamide, Docetaxel, measuring the PSA level 3 months after the start of treatment. Androgen deprivation therapy is carried out in the first 3 months of treatment with Zoladex — 3.6 mg s/c 1 time in 28 days, while in the first 10–14 days it is administered in combination with Ibuprofen in a daily dose of 60 mg rectally. After that, if a PSA level of less than 1 ng/ml is detected, androgen deprivation therapy is extended on its own for 6 months; if PSA is determined in the range from 1 to 10 ng/ml, prolong androgen deprivation therapy for 6 months in combination with Enzalutamide 160 mg orally daily is used; if PSA is determined at a level of more than 10 ng/ml, androgen deprivation therapy is carried out in combination with Enzalutamide 160 mg orally daily for 6 months. Docetaxel is additionally used for the first 3 months. After completion of the appropriate courses of treatment, PSA is re-determined and therapy is carried out according to the above schemes, depending on the obtained PSA values, and if the PSA level is less than 1 ng/ml twice in a row, the treatment is canceled with constant dynamic monitoring every 3–6 months.

EFFECT: use of the invention improves the quality and life expectancy of patients, reduces the likelihood of complications.

1 cl, 3 ex